ArticleAnnals of surgical treatment and research2023
Prognosis according to the timing of recurrence in breast cancer.
Article in Annals of surgical treatment and research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 18 citations in OpenAlex.
- Recurrence detection in patients with triple-negative breast cancer following the current standard of care: a microsimulation model.BMJ open · 2026Article
- Article
- Clinical and pathologic insights into early and late breast cancer relapses: a real-world analysis from the El Álamo IV registry.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- [Initial clinical experience with ribociclib in advanced HR+/HER2- breast cancer in Uruguay].Revista medica del Instituto Mexicano del Seguro Social · 2026Observational
- Mapping breast cancer lineage in radiation and immunotherapy using the REMAP mouse.bioRxiv : the preprint server for biology · 2026Article
- EPHA2-Ephrin-B1 cis-interaction drives an oncogenic reverse signaling, leading to the recurrence of oral cancer.Cell communication and signaling : CCS · 2026Article
- Simultaneous Omission of Sentinel Lymph Node Biopsy and Radiation in Older Women with Early ER+ Breast Cancer.Annals of surgical oncology · 2026Article
- Role of Axillary Restaging in Breast Cancer Patients with Preoperative Diagnosis of Isolated Chest Wall Recurrence After Mastectomy: A Literature Review.Medicina (Kaunas, Lithuania) · 2026Review
- BCL2-Associated Transcription Factor 1 Promotes SRC/Hypoxia-Inducible Factor 1 Subunit α-Mediated Cancer Stemness in Radioresistant Triple-Negative Breast Cancer.Oncology research · 2026Article
- Early recurrence predicts poor post-recurrence survival in young breast cancer patients: development and validation of a prognostic nomogram.American journal of cancer research · 2026Article
- "Going Flat" in Nipple-Sparing Mastectomy-An Analysis of Patient-Reported Outcome Measurements of Preliminary 57 Procedures.The breast journal · 2026Article
- Prognostic value of androgen receptor expression in ER-positive/HER2-negative breast cancer: evidence from a contemporary Chinese cohort.Frontiers in oncology · 2026Article
- Machine learning-based integration develops relapse related signature for predicting prognosis and indicating immune microenvironment infiltration in breast cancer.Scientific reports · 2025Article
- Article
- Epidemiology of early vs late recurrence among women with early stage estrogen receptor-positive breast cancer in the Pathways Study.Journal of the National Cancer Institute · 2024Article
- HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice.International journal of molecular sciences · 2024Article
- Reply on "Prognosis according to the timing of recurrence in breast cancer" (Ann Surg Treat Res 2023;104:1-9).Annals of surgical treatment and research · 2024Article
- Commentary on "Prognosis according to the timing of recurrence in breast cancer" (Ann Surg Treat Res 2023;104:1-9).Annals of surgical treatment and research · 2024Article
- Prognostic influences of B-cell lymphoma 2-positive expression on late recurrence in breast cancer.Annals of surgical treatment and research · 2023Article
- Comment on "Impact of Surgical Approach on Survival and Recurrence in Borderline and Malignant Phyllodes Tumours: A Systematic Review and Meta-Analysis".ANZ journal of surgeryArticle
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Clinically, breast cancer can be divided into 4 subtypes based on the presence of hormone receptors, human epidermal growth factor receptor 2 (HER2), and Ki-67. Because the pattern and time of recurrence vary according to the subtype, we evaluated whether there was a difference in overall survival (OS) among the subtypes according to the time and type of recurrence. Methods: A total of 2,730 patients who underwent breast cancer surgery were analyzed. Early and late recurrence were defined as recurrence within and after 5 years of diagnosis, respectively. Recurrence type was categorized as locoregional recurrence or systemic recurrence. Results: Hormone receptor-positive tumors were significantly more frequent in the late recurrence group than in the early recurrence group (estrogen receptor positive, 47.8% [early] Conclusion: The luminal B subtype had a high rate of late recurrence, and late recurrence was a poor prognostic factor for OS only in this subgroup. Therefore, further targeted treatments for luminal B breast cancer are needed and patients with this subtype require close long-term surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.